NCT06392425View on ClinicalTrials.gov

Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

Not yet recruitingOBSERVATIONAL

Enrollment

90

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

October 31, 2027

Conditions

Chronic Kidney Diseases

Interventions

OTHER

caspase 3 and ADAM 17 biomarkers

Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease

All Listed Sponsors

lead

Assiut University

OTHER